Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022

What's New

The two additional editions of the Course on Clinical Pharmacology of SARS-CoV-2 Antivirals, previously scheduled on 6 September and 1 November, have been postponed indefinitely. Make sure you are signed up for our newsletter to stay updated on developments.

About this Program

The COVID-19 pandemic has had a huge toll in terms of morbidity and mortality worldwide. Immunocompromised patients as well as patients over the age of 60 with comorbidities and underlying conditions are the most at risk of developing severe disease as a result of COVID-19. These patients are also exposed to multiple medications to treat their chronic conditions. Therefore, if they require treatment for COVID-19 with new SARS-CoV-2 antivirals, this can lead to a number of potential complex and serious drug-drug interactions that can result in severe side effects, or reduce the drugs’ therapeutic effect.

The Course on Clinical Pharmacology of SARS-CoV-2 Antivirals gathered healthcare professionals that prescribe oral antivirals for COVID-19 to discuss their therapeutic effects, the management of drug-drug interactions, and the identification of risk factors, as well as leaving ample time for case-based discussions.

General Information

Practical Information

We trust that the following information will assist you in organizing your participation in the Course on Clinical Pharmacology of SARS-CoV-2 Antivirals 2022.